Indications |
Parenteral Postoperative pain Adult: 40 mg slow IM or IV inj, then 20 or 40 mg every 6-12 hr as required. Max dose: 80 mg/day. Child: <18 yr: Not recommended. Elderly: <50 kg: 20 mg slow IV or IM inj, repeat to a max of 40 mg/day. Hepatic impairment: Mild impairment (Child-Pugh score 5-6): No dosage adjustment. Moderate impairment (Child-Pugh score 7-9): Half the usual dose, repeat to a max of 40 mg/day. Severe impairment (Child-Pugh score >9): Not recommended. Special Populations: Moderate hepatic impairment: Halved dose, max 40 mg/day. Reconstitution: Reconstitute with sodium chloride 0.9%, glucose 5%, or sodium chloride 0.45% with glucose 5%. |
Contraindications |
Aspirin or NSAID hypersensitivity; allergy to sulphonamides; inflammatory bowel disease; moderate to severe heart failure; ischaemic heart disease, peripheral arterial disease, or cerebrovascular disease; following CABG; active peptic ulceration; severe hepatic impairment (Child-Pugh score ≥10); pregnancy (3rd trimester) and lactation. |
Warnings / Precautions |
Elderly, children ; history of GI ulceration, perforation or bleed; oedema; dehydration; hyperlipidaemia; DM; hypertension; liver or kidney disease; concurrent infection. May impair ability to drive or operate machinery. |
Adverse Reactions |
Rash, ulcerations or any other signs of an allergic reaction; GI disturbances and bleeding; hypotension; hypertension; back pain; oedema; numbness; agitation or sleeping difficulties; anaemia; sore throat or difficulty breathing; pruritus; decreased urine output; jaundice, abnormal liver function; low platelet count; skin swelling, blistering or peeling; kidney failure; heart failure, heart attack, bradycardia, arrhythmia. Potentially Fatal: Anaphylaxis, Steven-Johnson syndrome, toxic epidermal necrolysis. |
Drug Interactions |
Enhances effects of oral anticoagulants (azapropazone and phenylbutazone); increases plasma concentrations of lithium, methotrexate, and cardiac glycosides; increased risk of nephrotoxicity with ACE inhibitors, ciclosporin, tacrolimus, or diuretics; reduces antihypertensive effects of some antihypertensives (ACE inhibitors, beta blockers, diuretics); occurrence of convulsions with quinolones; increases effects of phenytoin and sulfonylurea antidiabetics; increased risk of adverse effects with other NSAIDs (including aspirin) and misoprostol; risk of GI bleeding and ulceration increased with corticosteroids, SSRIs, the SNRI venlafaxine, the antiplatelets clopidogrel and ticlopidine, iloprost, erlotinib, sibutramine, alcohol, bisphosphonates, or pentoxifylline; increased risk of haematotoxicity with zidovudine; increased plasma concentrations with ritonavir; may alter the efficacy of mifepristone; metabolism may be decreased with CYP3A4 (e.g ketoconazole) and CYP2C9 inhibitors (e.g. fluconazole), or increased with enzyme inducers (e.g. carbamazepine, dexamethasone). See Below for More parecoxib Drug Interactions |
Mechanism of Actions |
Parecoxib is the prodrug of valdecoxib. It has a very high selectivity for inhibiting cyclo-oxygenase-2 (COX-2) mediated prostaglandin synthesis to reduce mediators of pain and inflammation. The selective inhibition of COX-2 is coupled with reduced GI toxicity, but associated increased risk for thrombotic events and renal impairment have been noted. Distribution: Plasma protein binding: approx 98%. Metabolism: Hydrolysed in the liver to its active metabolite, valdecoxib, and propionic acid; plasma half-life: 22 min. Excretion: Via urine; approx 70% of a dose appearing as inactive metabolites, <5% of a dose appears as unchanged valdecoxib in the urine. Trace amounts of unchanged drug in faeces. Elimination half-life: 8 hr. |
ATC Classification |
M01AH04 - parecoxib ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, coxibs. |
Available As |
|
Parecoxib
Post Review about Parecoxib Click here to cancel reply.
Parecoxib Containing Brands
Parecoxib is used in following diseases
Drug - Drug Interactions of Parecoxib
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.